AUM Biosciences Receives Human Research Ethics Committee Approval To Commence Phase II Clinical Trial Of AUM001 For Treatment Of Metastatic Colorectal Cancer In Australia
AUM Biosciences Receives Human Research Ethics Committee Approval To Commence Phase II Clinical Trial Of AUM001 For Treatment Of Metastatic Colorectal Cancer In Australia
AUM生物科學公司獲得人類研究倫理委員會批准在澳大利亞開始AUM001治療轉移性結直腸癌的第二階段臨牀試驗
AUM Biosciences Pte. Ltd. ("AUM"), a clinical-stage biotechnology company, advancing a clinical stage candidate and a broader pipeline designed to deploy multi-faceted inhibition strategies to reverse cancer resistance, today announced it has received Human Research Ethics Committee ("HREC") approval to commence a Phase II clinical trial of its selective translation inhibitor AUM001 in Australia. Ethics approval is confirmation that AUM has completed all the necessary pre-clinical safety and efficacy testing of AUM001 required to commence its Phase II clinical trial in Australia.
奧姆生物科學私人有限公司。臨牀階段生物技術公司AUM今天宣佈，它已獲得人類研究倫理委員會(“HREC”)的批准，將在澳大利亞開始其選擇性翻譯抑制劑AUM001的第二階段臨牀試驗。倫理批准是指確認AUM001已經完成了在澳大利亞開始其第二階段臨牀試驗所需的所有必要的臨牀前安全性和有效性測試。
"Ethics approval in Australia provides further validation of the study design recently approved under an IND by...
AUM首席執行官Vishal Do...
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間